Advertisement

Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer

      Prostate cancer is the third most common cause of cancer-related deaths among men in the United States. Twenty-five percent to 30% of sporadic castration-resistant prostate cancers are characterized by defects in DNA repair.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Grasso C.S.
        • Wu Y.M.
        • Robinson D.R.
        • et al.
        The mutational landscape of lethal castration-resistant prostate cancer.
        Nature. 2012; 487: 239-243
        • Tangutoori S.
        • Baldwin P.
        • Sridhar S.
        PARP inhibitors: a new era of targeted therapy.
        Maturitas. 2015; 81: 5-9
        • Gudmundsdottir K.
        • Ashworth A.
        The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.
        Oncogene. 2006; 25: 5864-5874
        • Fong P.C.
        • Boss D.S.
        • Yap T.A.
        • et al.
        Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers.
        N Engl J Med. 2009; 361: 123-134
        • Kim G.
        • Ison G.
        • McKee A.E.
        • et al.
        FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy.
        Clin Cancer Res. 2015; 21: 4257-4261
        • Murai J.
        • Shar-yin N.H.
        • Das B.B.
        • et al.
        Trapping of PARP1 and PARP2 by clinical PARP inhibitors.
        Cancer Res. 2012; 72: 5588-5599
        • Drew Y.
        • Ledermann J.
        • Hall G.
        • et al.
        Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
        Br J Cancer. 2016; 114: 723-730
        • Mirza M.R.
        • Monk B.J.
        • Herrstedt J.
        • et al.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N Engl J Med. 2016; 375: 2154-2164
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Tischkowitz M.
        • Xia B.
        PALB2/FANCN: recombining cancer and Fanconi anemia.
        Cancer Res. 2010; 70: 7353-7359
        • Evans M.K.
        • Longo D.L.
        PALB2 mutations and breast-cancer risk.
        N Engl J Med. 2014; 371: 566-568
        • Churpek J.E.
        • Marquez R.
        • Neistadt B.
        • et al.
        Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
        Cancer. 2016; 122: 304-311
        • Pritchard C.C.
        • Mateo J.
        • Walsh M.F.
        • et al.
        Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
        N Engl J Med. 2016; 375: 443-453
        • Mateo J.
        • Boysen G.
        • Barbieri C.E.
        • et al.
        DNA repair in prostate cancer: biology and clinical implications.
        Eur Urol. 2017; 71: 417-425
        • Ricks T.K.
        • Chiu H.J.
        • Ison G.
        • et al.
        Successes and challenges of PARP inhibitors in cancer therapy.
        Front Oncol. 2015; 5: 222
        • Kaufman B.
        • Shapira-Frommer R.
        • Schmutzler R.K.
        • et al.
        Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
        J Clin Oncol. 2014; 33: 244-250
        • Morton L.M.
        • Dores G.M.
        • Tucker M.A.
        • et al.
        Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.
        Blood. 2013; 121: 2996-3004
        • Brenner D.J.
        • Curtis R.E.
        • Hall E.J.
        • Ron E.
        Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.
        Cancer. 2000; 88: 398-406
        • Moon K.
        • Stukenborg G.J.
        • Keim J.
        • Theodorescu D.
        Cancer incidence after localized therapy for prostate cancer.
        Cancer. 2006; 107: 991-998
        • Wang R.
        • Zeidan A.M.
        • Yu J.B.
        • et al.
        Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study.
        Prostate. 2017; 77: 437-445
        • Odo U.
        • Vasudevamurthy A.
        • Sartor O.
        Acute promyelocytic leukemia after treatment of metastatic castrate-resistant prostate cancer with radium-223.
        Clin Genitourin Cancer. 2017; 15: e501-e502
        • Varkaris A.
        • Gunturu K.
        • Kewalramani T.
        • Tretter C.
        Acute myeloid leukemia after radium-223 therapy: case report.
        Clin Genitourin Cancer. 2016; ([e-pub ahead of print])https://doi.org/10.1016/j.clgc.2016.11.002
      1. ClinicalTrials.gov.
        (Available at:) (Accessed: July 29, 2017)